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Abstract
Background: Health outcomes could be improved if women at high risk for osteoporotic fracture were matched
to effective treatment. This study determined the extent to which treatment for osteoporosis/osteopenia
corresponded to the presence of specific risk factors for osteoporotic fracture.
Methods: This retrospective analysis of the United States 2007 National Health and Wellness Survey included
women age ≥ 40 years who reported having a diagnosis of osteoporosis (69% of 3276) or osteopenia (31% of
3276). Patients were stratified by whether they were or were not taking prescription treatment for osteoporosis/
osteopenia. Using 34 patient characteristics as covariates, logistic regression was used to determine factors
associated with treatment.
Results: Current prescription treatment was reported by 1800 of 3276 (54.9%) women with osteoporosis/
osteopenia. The following factors were associated with receiving prescription treatment: patient-reported diagnosis
of osteoporosis (versus osteopenia); previous bone mineral density test; ≥ 2 fractures since age 50; older age; lower
body mass index; better physical functioning; postmenopausal status; family history of osteoporosis; fewer
comorbidities; prescription insurance coverage; higher total prescription count; higher ratio of prescription costs to
monthly income; higher income; single status; previous visit to a rheumatologist or gynecologist; and 1 or 2
outpatient visits to healthcare provider (vs. none) in the prior 6 months. Glucocorticoid, tobacco, and daily alcohol
use were risk factors for fracture that were not associated with treatment.
Conclusions: There is a mismatch between those women who could benefit from treatment for osteoporosis and
those who are actually treated. For example, self-reported use of glucocorticoids, tobacco, and alcohol were not
associated with prescription treatment of osteoporosis. Other clinical and socioeconomic factors were associated
with treatment (e.g. prescription drug coverage and higher income) or not (e.g. comorbid osteoarthritis and
anxiety) and could be opportunities to improve care.
Background
Osteoporosis is a systemic skeletal disorder character-
ized by low bone mass, structural deterioration of bone
tissue, and an increased vulnerability to low-trauma
fractures [1,2]. In the United States (US), an estimated
10 million people are affected by osteoporosis, and an
additional 34 million are believed to have low bone
mass, or osteopenia, placing them at increased risk for
osteoporosis [3,4]. Low bone mass density (BMD)
results in 1.5 million fractures annually, exacting a
national cost of 14 billion dollars, and often, a profound
personal cost [3,5]. These fractures are associated with
chronic pain, increased dependence, reduced mobility,
deformity, depression, loss of self-esteem, increased
rates of hospitalization, and heavy personal socioeco-
nomic burden [3,5,6].
Several pharmacologic agents approved by US Food
and Drug Administration (FDA), including bisphospho-
nates, raloxifene, estrogen with or without progestin,
and teriparatide, have shown efficacy in slowing or halt-
ing bone loss and reducing fracture risk [7,8]. Targeting
effective treatments for osteoporosis to individuals at
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avoid unnecessary treatment of those at low risk for
fracture.
Many medical specialty societies, academic institu-
tions, professional consortiums, and private non-profit
organizations have published guidelines for management
of osteoporosis, in which treatment decisions are based
primarily on BMD test results in combination with indi-
vidual patient characteristics such as advanced age,
family history, and tobacco use [9-13]. The World
Health Organization (WHO) developed a country-speci-
fic fracture risk assessment tool (FRAX) for predicting a
patient’s 10-year probability of osteoporosis-related frac-
ture based on age, gender, previous fracture history,
BMD, low body mass index (BMI), use of oral glucocor-
ticoid therapy, osteoporosis secondary to another condi-
tion, parental history of hip fracture, current smoking,
and alcohol intake of 3 or more drinks per day [14-16].
FRAX plays a pivotal role in guiding recommendations
for treatment by the National Osteoporosis Foundation.
While postmenopausal women or men over 50 with a
T-score of -2.5 or lower at the hip or spine or with a
prior hip or spine fracture should definitely be treated,
the 2008 Clinician’s Guide uses the absolute fracture
risk calculated from the US-adapted FRAX algorithm to
help determine whether to treat [17]; thresholds for
treatment are a ≥ 3% probability of osteoporosis-related
hip fracture or a ≥ 20% risk of any osteoporosis-related
fracture in the subsequent 10 years [18,19]. Despite
advances in the diagnosis and treatment of osteoporosis,
it remains underrecognized and undertreated in the US
[20].
The primary objective of this study is to identify the
patient-reported factors that correlate with receipt or
nonreceipt of prescription treatment for osteoporosis or
osteopenia in women who report having been diagnosed
with the condition. A secondary objective is to compare
the factors identified in this study to known clinical risk
factors for osteoporotic fracture, using risk factors
included in the FRAX algorithm.
Methods
Design
Data for this analysis were obtained from the 2007 US
National Health and Wellness Survey (NHWS) [21], an
annual, cross-sectional study of healthcare attitudes,
behaviors, and outcomes. NHWS data are obtained
from a web-based consumer panel, sampled to reflect
the total US adult population. Participants recruited
through internet advertising agreed to receive email
invitations to participate in online surveys in exchange
for sweepstakes entry and reward points redeemable for
consumer products. Inclusion criteria for participation
i nt h e2 0 0 7U SN H W Sw e r ea g e≥ 18 years, residence
in the US, and ability to read and write English. The
sample is drawn from the panel maintained by Light-
speed Research and invitations to participate in the
NHWS are sent regardless of health status. The number
of respondents has steadily increased each year, from
16,619 in 1998 to 63,012 in 2007. All 50 states and the
District of Columbia and represented. Results are
adjusted to reflect the total adult population by using
known population incidences for key subgroups and
weighting variables (gender, age, and race/ethnicity)
using data from the previous year’s Current Population
Survey (Annual Demographics File) of the US Census
Bureau. The NHWS study protocol and questionnaire
were reviewed and approved by the Essex Investigational
Review Board, Inc. (Lebanon, NJ, US). All participants
provided informed consent prior to beginning the sur-
vey, and all identifying information was removed.
Participants
The current analysis was limited to data from female
respondents, age ≥ 40 years, who reported a physician
diagnosis of osteoporosis or osteopenia.
Measurements
Demographic and Socioeconomic Characteristics
Demographic measures in the NHWS included age,
race/ethnicity, marital status, and number of children in
household. Age was categorized as 40 to 54 (reference),
55 to 64, 65 to 74, and ≥ 75 years. Race/ethnicity was
categorized as white (reference), African American, His-
panic, and other. Marital status was categorized as mar-
ried/partnered, single, divorced/separated, or widowed.
Number of children under the age of 18 in the house-
hold was assessed as a discrete continuous variable.
Socioeconomic characteristics included education,
income, and employment status. Education was categor-
ized as either having or not having graduated from col-
lege. Annual 2006 household income was categorized
($0-24,999; $25,000-49,999; $50,000-74,999; $75,000-
99,999; $100,000-124,999; $125,000-149,999; and ≥
$150,000) and treated as an ordinal variable, with mean
substitution of missing values due to responses of
“decline to answer.” To adjust for potentially different
characteristics of those who declined to answer, a
dummy variable for missing income was included in the
final model. Working status was coded as employed or
not employed.
General Clinical Characteristics
Mental and physical functioning were evaluated using
the summary measures of the standard 12-item Medical
Outcomes Study Short Form survey, US version 2.0 (SF-
12v2), a patient-rated metric that includes questions
regarding general health, bodily pain, mental health,
vitality, social functioning, role limitations due to
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emotional problems over the 4 weeks prior to complet-
ing the survey. Like the 36-item Short Form survey, the
SF-12v2 provides physical and mental summary scores
normalized for the US adult population with a mean of
50 and a standard deviation of ± 10, where higher scores
represent better functioning [22].
The assignment of osteoporosis or osteopenia was
made based on the subject self-reporting a physician
diagnosis of osteoporosis or osteopenia, and the year of
diagnosis. Subjects were also asked to self-report receipt
of bone mineral density scan, current use of prescription
medications to treat osteoporosis/osteopenia, and the
number of bone fractures since age of 50. All respon-
dents who reported taking a prescription medication to
treat osteopenia or osteoporosis were asked to identify
the medications they used. Choices were presented as
the branded names and included “Actonel”, “Boniva”,
“Evista”, “Forteo”, “Fosamax”, “Fosamax Plus D”, “Mia-
calcin”, “hormonal treatment”,a n d“Other” (asked to
specify using free text). Reclast (zoledronic acid) was not
included as a possible response because it was not
approved to treat osteoporosis until 2007 after the sur-
vey was initiated. Family health history of osteoporosis
included affected parents, grandparents, siblings, or
other blood relative.
Clinical characteristics assessed as continuous vari-
ables included years since osteoporosis/osteopenia diag-
nosis, days exercised in the past month, BMI, and total
number of prescription medications used for all condi-
tions. Menopausal status, cigarette use, daily alcohol
use, family history of osteoporosis, and disability pre-
venting employment were handled as dichotomous (yes/
no) variables. Other dichotomous variables included
having a diagnosis of osteoporosis (as compared to
osteopenia), having had a BMD test, and having under-
gone a hysterectomy with oopherectomy. For partici-
pants age 50 years and older, the number of fractures
(any kind) occurring after age 50 was coded as 0 (refer-
ence), 1, or ≥ 2, and missing values were included as a
dummy variable. Glucocorticoid use included beta-
methasone, cortisone, dexamethasone, fludrocortisone,
hydrocortisone, methylprednisolone, prednisolone, pre-
dnisone, or triamcinolone, regardless of route of admin-
istration and condition being treated. Duration or past
history of glucocorticoid use were not available from the
survey.
Comorbidity
Both physical and psychiatric comorbidities were
assessed. Overall physical comorbidity was assessed
using an adaptation of the Charlson Comorbidity Index
(CCI) [23], in which scores are assigned based on the
presence or absence of 22 conditions. Conditions in the
NHWS were matched to and assigned the point values
of comparable conditions in the CCI. The presence or
absence of back pain and osteoarthritis, which are not
included as part of the CCI, were considered separately
due to the potential relevance to osteoporosis diagnosis
and/or sequelae. In order to account for both physical
and mental comorbidity, we included data on the pre-
sence of anxiety and depression.
Healthcare Utilization and Costs
Healthcare utilization included inpatient and outpatient
resource use in the previous 6 months. Hospitalization
was considered as a dichotomous (yes/no) variable. Vis-
its to primary care physicians, endocrinologists, gynecol-
ogists, nurse practitioners, rheumatologists, and
orthopedic surgeons were assessed (yes/no) individually.
Total number of provider visits (1-2, 3-6, and ≥ 7v i s i t s ,
with none as the reference group) was treated as catego-
rical variable.
Prescription coverage and use of generic medication
and other cost-cutting strategies were considered as
dichotomous (yes/no) variables. Cost-cutting strategies
included taking less medication, cutting tablets in half,
and taking fewer pills than prescribed. Out-of-pocket
monthly expenditure for prescription medication was
calculated as a proportion of monthly income and
handled as a continuous variable.
Data Analysis
Univariate Analyses
Descriptive statistics were calculated for all participants
to determine the distribution of potential correlates.
Patients were stratified by their use of prescription (ver-
sus no prescription) treatment for osteoporosis. All
measures were compared between the prescription
group and the no prescription group, using chi-square
analyses for categorical variables and Student t tests for
continuous variables. Tests of hypotheses were per-
formed at a 2-sided significance level of 5%.
Multivariate Analyses
We conducted a logistic regression analysis to determine
the independent association of factors that potentially
correlate with receipt of prescription treatment for osteo-
porosis/osteopenia. The dependent variable was use of
prescription treatment versus no prescription treatment.
All covariates were included in the same regression
model but are presented separately to facilitate discussion
of 3 categories of possible predictors. Other than the
fracture risk factors, other covariates included in the
model were broadly classified as health status and beha-
vior variables or demographic and socioeconomic charac-
teristics. Missing data were handled as discussed in the
description of the variables. Data analyses were con-
ducted with SPSS
®, version 12 (SPSS Inc., Chicago, IL).
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Of the 62,833 people included in the final NHWS data-
set, 3276 (5.2%) were women over the age of 40 years
who had been diagnosed with osteoporosis or osteope-
nia. Of these, 1800 (54.9%) reported using prescription
medication for osteoporosis/osteopenia (Figure 1). The
characteristics of the participants are summarized in
T a b l e1 .M o r ew o m e nh a do s t e o p o r o s i s( 6 9 % )t h a n
osteopenia (31%). About half reported having a family
history of osteoporosis and approximately 30% had
experienced a fracture themselves. Over 85% of the
study sample reported having undergone BMD testing
and most women described themselves as postmenopau-
sal (69.2%). Nearly all participants (90.5%) were white
and nearly a third had a college degree. Over 80%
reported having prescription drug coverage.
Participants who received prescription treatment for
osteoporosis/osteopenia differed from those not receiv-
ing treatment as follows: older age, lower BMI, less
tobacco use, better general health (e.g. SF-12 score),
more days with exercise, fewer comorbidities, more
highly educated, more commonly widowed, higher
income, less likely to be employed, and better prescrip-
tion drug coverage.
After adjusting for differences in measured character-
istics between the treated and untreated groups, several
factors were associated with receiving treatment. The
odds ratios for receiving treatment are presented in
Tables 2, 3, and 4. Some established risk factors were
correlated with treatment: older age, lower BMI, having
had 2 or more fractures after age 50, and a family his-
tory of osteoporosis (Table 2). Having a diagnosis of
osteoporosis (vs. osteopenia) was also significantly corre-
lated with treatment. Current glucocorticoid use, current
tobacco use, and daily alcohol use were not correlated
with treatment, even though these are established risk
factors for fracture.
We identified the following health status and behavior
factors (Table 3) associated with prescription treatment:
higher SF-12v2 Physical Summary score, having a BMD
test in the past (regardless of result), postmenopausal
status, lower comorbid burden, increased number of
non-osteoporosis related prescription medications,
absence of osteoarthritis, absence of anxiety, number of
visits to gynecologists or rheumatologists in the past 6
months, and 1 to 2 (versus none) health care provider
visits in the past 6 months. Socioeconomic and demo-
graphic variables (Table 4) that were significantly asso-
ciated with receiving treatment included having
prescription coverage, higher income, greater proportion
of monthly income spent on prescription medication,
and being single (vs. married).
Discussion
Our analyses suggest that there is a substantial mis-
match between those women who could benefit from
treatment for osteoporosis and those who are actually
treated. Women who are older, with a previous fracture,
lower BMI, and family history of osteoporosis are being
appropriately targeted for treatment. For example, these
3 risk factors are used to predict fracture risk in FRAX,
an evidence-based risk model sponsored by the World
Health Organization. Women with other established risk
factors (glucocorticoid use, tobacco use, and daily alco-
hol use) were not more likely to be treated.
Patients with osteoarthritis and anxiety were less likely
to receive prescription therapy for osteoporosis, regard-
less of their risk for osteoporotic fracture. It may be that
chronic mental and physical pain conditions such as
these compete and win for the clinician’s attention over
more silent conditions like osteopenia and early osteo-
porosis. Likewise, patients with chronic illness facing
ongoing physical, emotional, and economic burden may
prioritize treatment of a more painful condition such as
osteoarthritis over a less painful one. With respect to
osteoarthritis, the bone loss might appear to be less
severe due to the underlying physical effects of osteoar-
thritis. The inverse association between osteoarthritis
and osteoporosis might partially explain why patients
with osteoporosis and osteoarthritis were less likely to
receive treatment for osteoporosis [24,25], though it
does not fully explain lower levels of treatment among
those at high fracture risk. Anxious patients may be
more reluctant to take medication because they may be
more concerned about treatment side effects than non-
anxious patients.
Our findings suggest that treatment patterns for
osteoporosis depend on other socioeconomic issues
such as income, having prescription drug coverage, and
NHWS Sample 
N=62,833  
Men in NHWS 
n=30,100  
Women in NHWS 
n=32,733  
Study Sample  
Age ≥40 years and diagnosis of 
osteoporosis or osteopenia 
n=3276  
Women Not Meeting  
Entry Criteria 
<40 years or no diagnosis of 
osteoporosis or osteopenia 
n=29,457  
Prescription Group 
n=1800 
No Prescription Group 
n=1476 
Figure 1 Study population flow chart.A b b r e v i a t i o n s :n / N=
number of patients; NHWS = National Health and Wellness Survey.
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status
Study
Sample
(N = 3276)
No
Prescription
(n = 1476)
Prescription
Treatment
(n = 1800)
P value
Risk factors for fracture
Age (mean) 64.4 63.3 65.2 < .001
Fracture history, %
None 62.9 64.2 61.7 .14
1 15.3 14.7 15.8 .37
≥ 2 14.1 11.0 16.6 < .001
Osteoporosis, % 69.0 63.3 73.6 < .001
BMI (mean) 28.0 28.7 27.5 < .001
Family history of osteoporosis, % 50.6 49.1 51.9 .10
Glucocorticoid use, % 5.8 5.6 5.9 .64
Tobacco use, % 21.3 24.1 19.1 .001
Daily alcohol use, % 5.7 5.6 5.8 .73
Health Status
SF-12v2 score
Physical summary 40.4 39.1 41.4 < .001
Mental summary 49.1 48.3 49.7 < .001
Exercise in past month, d 6.8 6.4 7.2 .01
Years since diagnosis 6.4 6.3 6.5 .48
BMD testing, % 85.5 79.3 90.6 < .001
Postmenopausal, % 69.2 64.4 73.1 < .001
Hysterectomy with oophorectomy, % 29.1 28.6 29.6 .55
Comorbidity index score 1.02 1.07 0.97 .04
Prescription medications currently using for conditions other than osteoporosis, median 5.1 5.0 5.2 .13
Back pain, % 32.1 36.0 28.8 < .001
Osteoarthritis, % 50.5 55.6 46.3 < .001
Anxiety, % 25.2 30.3 21.1 < .001
Depression, % 24.0 26.6 21.9 .002
Disabled, % 8.0 8.7 7.4 0.18
Hospitalized (past 6 months), % 12.5 12.3 12.7 .69
Provider visits (6 months),%
PCP 84.2 81.7 86.2 .001
Endocrinologist 5.3 4.9 5.6 .40
Gynecologist 16.0 14.3 17.4 .02
Nurse practitioner 15.0 15.4 14.7 .53
Orthopedist 12.8 13.1 12.6 .69
Rheumatologist 9.0 7.5 10.2 .008
Provider visits (6 months), %
1-2 45.2 41.7 48.2 < .001
3-6 35.6 36.7 34.8 .27
≥ 7 10.9 10.8 10.9 .92
Demographic and Socioeconomic Characteristics
Race/ethnicity, %
White 90.5 89.8 91.0 .27
African American 3.5 3.0 3.9 .17
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95% Confidence Interval
Odds Ratio Low High P value
Age cohort (y)
40-55 Reference
55-64 1.33 0.98 1.79 .07
65-74 1.43 1.05 1.94 .02
≥ 75 1.17 0.79 1.72 .44
Fracture history
0 Reference
1 1.02 0.82 1.26 .86
≥ 2 1.50 1.19 1.88 .001
Osteoporosis (vs. osteopenia) 2.08 1.75 2.47 < .001
BMI 0.98 0.97 0.99 .003
Family history of osteoporosis 1.22 1.05 1.42 .01
Glucocorticoid use 0.84 0.60 1.18 .32
Tobacco use 0.84 0.69 1.02 .08
Daily alcohol use 0.87 0.63 1.20 .39
Abbreviations: BMD = bone mineral density; BMI = body mass index.
Variables listed in Tables 2, 3, and 4 were all included in the same regression model but are presented separately to highlight the 3 different groups of factors.
Table 1 Characteristics of women with osteoporosis or osteopenia diagnosis according to prescription treatment sta-
tus (Continued)
Hispanic 2.7 3.1 2.3 .17
Other 3.3 4.0 2.7 .04
Graduated college, % 27.7 25.7 29.4 .02
Employed, % 25.3 27.6 23.4 .005
Prescription coverage, % 82.9 79.0 86.1 < .001
Income (thousand dollars/y), %
<2 5 24.9 27.2 23.1 .02
25- < 50 30.7 31.4 30.1
50- < 75 17.9 18.0 17.9
75- < 100 8.2 7.1 9.1
100- < 125 3.2 2.6 3.7
125-150 1.7 1.8 1.6
≥ 150 2.4 2.2 2.6
Out-of-pocket spending on prescriptions as a proportion of income 0.05 0.05 0.06 .05
Cost cutting actions, % 16.4 17.8 15.3 .05
Ask for generic, % 36.9 36.2 37.4 .48
Children in home 0.18 0.22 0.15 .002
Marital status
Married/partnered 56.9 57.7 56.2 .39
Single 4.3 4.1 4.6 .49
Divorced/separated 20.8 22.0 19.9 .14
Widowed 17.9 16.2 19.3 .02
Abbreviations: BMD = bone mineral density; BMI = body mass index; d = days; N = total number in study sample; n = number in subgroup; PCP = primary care
provider; SF-12v2 = Short Form-12, version 2.0; y = year.
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delineate these issues, we hypothesize that some factors,
like comorbid osteoarthritis, might play an important
role when the decision is made (or not) to initiate ther-
apy. Others, like prescription drug coverage or income
could be associated with persistence, or lack thereof.
In addition to providing an analysis of treatment pat-
terns in relation to fracture risk, we built upon prior
studies of prescription drug use in osteoporosis by
examining a very large survey sample and including a
wide breadth of patient-reported data [20]. In a meta-
analysis addressing guideline adherence, predictors of
treatment, and programs to assess improved care, Solo-
mon et al. reported that no factor consistently predicted
treatment [26]. Brennan et al. identified college educa-
tion, higher income, more frequent medical care, and
care by a gynecologist as correlates of prescription
treatment [27]. Various other studies have shown that
lower income is associated with lower BMD testing and
prescription treatment in managed care settings [28],
among patients with Medicare [29], and within a
national healthcare system [30]. In another study of glu-
cocorticoid-induced osteoporosis, patients with more
comorbid conditions were generally less likely to receive
prescription treatment for osteoporosis than patients
with less comorbid burden. Only 42% of patients who
were taking glucocorticoids received prescription treat-
ment, and only 23% underwent bone densitometry [31].
Our study has a number of important limitations. One
was the absence of BMD test results or clinical informa-
tion from medical records, such as were analyzed in a
recent study that provides complimentary information
to our work [32]. The self-report of medical procedures,
like a BMD test, could be prone to a lack of subject
Table 3 Association between health status and behavior variables and prescription treatment of osteoporosis/
osteopenia
95% Confidence Interval
Odds Ratio Low High P value
SF-12v2 score
Physical summary 1.02 1.01 1.03 < .001
Mental summary 1.00 0.99 1.01 .76
Exercise in past month, d 1.00 0.99 1.01 .74
Years since diagnosis 1.00 0.98 1.01 .58
BMD testing 3.37 2.32 4.88 < .001
Postmenopausal 1.22 1.01 1.46 .04
Hysterectomy with oophorectomy 0.98 0.83 1.15 .78
Comorbidity index score 0.92 0.86 0.98 .02
Number of prescription medications currently using for conditions other than osteoporosis 1.07 1.04 1.09 < .001
Back pain 0.92 0.77 1.11 .40
Osteoarthritis 0.69 0.59 0.81 < .001
Anxiety 0.63 0.51 0.78 < .001
Depression 1.03 0.82 1.30 .77
Disabled 1.29 0.93 1.78 .13
Hospitalized (past 6 months) 1.10 0.86 1.39 .45
Provider visits by type
PCP 1.05 0.77 1.41 .77
Endocrinologist 1.11 0.79 1.56 .55
Gynecologist 1.31 1.05 1.63 .02
Nurse practitioner 1.00 0.80 1.25 > .99
Orthopedist 1.00 0.78 1.28 > .99
Rheumatologist 1.40 1.05 1.86 .02
Provider visits by number
0 reference
1-2 1.69 1.13 2.52 .01
3-6 1.38 0.88 2.17 .16
≥ 7 1.41 0.82 2.42 .22
Abbreviations: d = days; PCP = primary care provider; SF-12v2 = Short Form-12, version 2.0.
Variables listed in Tables 2, 3, and 4 were all included in the same regression model but are presented separately to highlight the 3 different groups of factors.
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glucocorticoids was only qualitatively addressed and did
not include former use. A substantial proportion of
patients might be using low doses, inhaled formulations,
or short durations of therapy that might not significantly
affect their fracture risk; others might have previously
used glucocorticoids for extended periods of time. Our
risk factor variables were not sufficient to reliably calcu-
late each patient’s risk of fracture. One particularly
important difference is that our study included all routes
of administration while predictive models like FRAX
include only oral glucocorti c o i d s .H o w e v e r ,p r e v i o u s
studies have demonstrated the undertreatment of
patients using glucocorticoids [31,33], which is consis-
tent with our findings. We could not determine at the
individual patient level which patients who needed treat-
ment received it and which patients were being treated
u n n e c e s s a r i l yb e c a u s ew ew e r eu n a b l et oe x a m i n et h e
composite risk for fracture of individual patients. Our
sample provides no information on patients with
undiagnosed osteoporosis or osteopenia, who are esti-
mated to comprise over 50% of those with the condition
[34], The small numbers of non-white participants lim-
ited our ability to detect differences between groups
based on race or ethnicity. Questions on the NHWS did
not allow us to distinguish between undertreatment,
problems with initiating therapy, or lack of persistence,
which has been shown to be a significant problem in
treatment of this disease [35], Finally, the cross-sectional
study design used in this analysis did not permit infer-
ences regarding causality.
Conclusions
Efforts to reduce the association between undertreat-
ment and lower income and lack of prescription cover-
age are warranted, especially as treatments become less
expensive with the introduction of generic bisphospho-
nates in the US. Further research is needed to under-
stand how fracture risk correlates with evidence-based
clinical decisions. Some risk factors correlated with
treatment while others did not and thus it would be
valuable to identify and address the barriers to treat-
ment that exist for women who smoke or drink heavily.
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